AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) Amphoteric liposomes having an isoelectric point of between 4 and 8, wherein the liposomes comprise at least one amphipatic molecule with a positive charge ~~carrier~~ and at least one amphipatic molecule with a negative charge ~~carrier which is different from the positive charge carrier or at least one amphoteric charge carrier~~.

2. (Original) The amphoteric liposomes of claim 1, wherein the liposomes have an isoelectric point of between 5 and 7.

3. (Currently amended) Amphoteric liposomes ~~The amphoteric liposomes of claim 1~~, wherein the liposomes comprise at least one amphipatic molecule with a positive and a negative charge, ~~amphoteric charge carrier, the~~ wherein the amphoteric charge carrier has ~~having~~ an isoelectric point of between 4 and 8.

4. (Canceled)

5. (Currently amended) The amphoteric liposomes of claim 3 ~~Amphoteric liposomes~~, wherein the liposomes further comprise at least one amphipatic ~~amphoteric~~ molecule with a positive charge ~~carrier~~ and/or at least one amphipatic molecule with a ~~anionic and/or cationic charge carrier~~ negative charge.

6. (Original) Amphoteric liposomes of claim 5, wherein the liposomes have an isoelectric point of between 5 and 7.

7. (Currently amended) The amphoteric liposomes of claim 1, 2, 3, 5 or 6, wherein the liposomes further comprise a neutral lipid, selected from the group consisting of phosphatidyl choline,

phosphatidyl ethanolamine, cholesterol, tetraether lipid, ceramide, sphigolipid and/or diacryl glycerol.

8. (Currently amended) The amphoteric liposomes of claim 1, wherein the liposomes have an average size of between 50 and 1000 nm~~, preferably between 70 and 250 nm and particularly between 60 and 130 nm~~.

9. (Previously presented) The amphoteric liposomes of claim 1, wherein the liposomes comprise an active ingredient.

10. (Previously presented) The amphoteric liposomes of claim 9, wherein the active ingredient is a protein, a peptide, a DNA, an RNA, antisense nucleotide and/or a decoy nucleotide.

11. (Previously presented) The amphoteric liposomes of claim 1, wherein at least 80 percent of the active ingredient is in the interior of the liposome.

12. (Withdrawn) A method for charging liposomes with active ingredients of claim 1, wherein a defined pH is used for the encapsulation and a second pH is used for separating the material, which has not been bound.

13. (Withdrawn) The method for charging liposomes with active ingredient of claim 1, wherein the liposomes are permeabilized and closed off at a defined pH.

14-19. (Canceled)

20. (Canceled)

21. (New) The amphoteric liposomes of claim 8, wherein the liposomes have an average size of

between 70 and 250 nm.

22. (New) The amphoteric liposomes of claim 8, wherein the liposomes have an average size of between 60 and 130 nm.